Beta-blockers after myocardial infarction

Do benefits ever outweigh risks in asthma?

Carol C. Chafin, Judith E. Soberman, Kutay Demirkan, Timothy Self

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

β-Blockers are well documented to prolong life in patients after myocardial infarction (MI), yet patients who also have asthma are frequently and understandably denied this therapy. We reviewed the literature (via MEDLINE) for the past 35 years for β-blocker-induced asthma, and reexamined potential β-blocker use in the context of NIH guidelines for asthma classification and management. Because β-blockers can cause fatal or life-threatening asthma, their use should be avoided in moderate to severe persistent asthmatics. Benefits of low-dose β1-blockers (e.g. atenolol 50 mg daily) may outweigh risks in some patients with mild intermittent or well-controlled mild persistent asthma. Further study is needed to verify that low doses of β1-blockers are effective in prolonging life after MI, and that use specifically in mild intermittent or mild persistent asthma per NIH classification is safe. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalCardiology
Volume92
Issue number2
DOIs
StatePublished - Jan 1 1999

Fingerprint

Asthma
Myocardial Infarction
Atenolol
MEDLINE
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Beta-blockers after myocardial infarction : Do benefits ever outweigh risks in asthma? / Chafin, Carol C.; Soberman, Judith E.; Demirkan, Kutay; Self, Timothy.

In: Cardiology, Vol. 92, No. 2, 01.01.1999, p. 99-105.

Research output: Contribution to journalReview article

Chafin, CC, Soberman, JE, Demirkan, K & Self, T 1999, 'Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?', Cardiology, vol. 92, no. 2, pp. 99-105. https://doi.org/10.1159/000006955
Chafin, Carol C. ; Soberman, Judith E. ; Demirkan, Kutay ; Self, Timothy. / Beta-blockers after myocardial infarction : Do benefits ever outweigh risks in asthma?. In: Cardiology. 1999 ; Vol. 92, No. 2. pp. 99-105.
@article{6b841eeee86d4d6190e98b28361fba6b,
title = "Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?",
abstract = "β-Blockers are well documented to prolong life in patients after myocardial infarction (MI), yet patients who also have asthma are frequently and understandably denied this therapy. We reviewed the literature (via MEDLINE) for the past 35 years for β-blocker-induced asthma, and reexamined potential β-blocker use in the context of NIH guidelines for asthma classification and management. Because β-blockers can cause fatal or life-threatening asthma, their use should be avoided in moderate to severe persistent asthmatics. Benefits of low-dose β1-blockers (e.g. atenolol 50 mg daily) may outweigh risks in some patients with mild intermittent or well-controlled mild persistent asthma. Further study is needed to verify that low doses of β1-blockers are effective in prolonging life after MI, and that use specifically in mild intermittent or mild persistent asthma per NIH classification is safe. Copyright (C) 2000 S. Karger AG, Basel.",
author = "Chafin, {Carol C.} and Soberman, {Judith E.} and Kutay Demirkan and Timothy Self",
year = "1999",
month = "1",
day = "1",
doi = "10.1159/000006955",
language = "English (US)",
volume = "92",
pages = "99--105",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Beta-blockers after myocardial infarction

T2 - Do benefits ever outweigh risks in asthma?

AU - Chafin, Carol C.

AU - Soberman, Judith E.

AU - Demirkan, Kutay

AU - Self, Timothy

PY - 1999/1/1

Y1 - 1999/1/1

N2 - β-Blockers are well documented to prolong life in patients after myocardial infarction (MI), yet patients who also have asthma are frequently and understandably denied this therapy. We reviewed the literature (via MEDLINE) for the past 35 years for β-blocker-induced asthma, and reexamined potential β-blocker use in the context of NIH guidelines for asthma classification and management. Because β-blockers can cause fatal or life-threatening asthma, their use should be avoided in moderate to severe persistent asthmatics. Benefits of low-dose β1-blockers (e.g. atenolol 50 mg daily) may outweigh risks in some patients with mild intermittent or well-controlled mild persistent asthma. Further study is needed to verify that low doses of β1-blockers are effective in prolonging life after MI, and that use specifically in mild intermittent or mild persistent asthma per NIH classification is safe. Copyright (C) 2000 S. Karger AG, Basel.

AB - β-Blockers are well documented to prolong life in patients after myocardial infarction (MI), yet patients who also have asthma are frequently and understandably denied this therapy. We reviewed the literature (via MEDLINE) for the past 35 years for β-blocker-induced asthma, and reexamined potential β-blocker use in the context of NIH guidelines for asthma classification and management. Because β-blockers can cause fatal or life-threatening asthma, their use should be avoided in moderate to severe persistent asthmatics. Benefits of low-dose β1-blockers (e.g. atenolol 50 mg daily) may outweigh risks in some patients with mild intermittent or well-controlled mild persistent asthma. Further study is needed to verify that low doses of β1-blockers are effective in prolonging life after MI, and that use specifically in mild intermittent or mild persistent asthma per NIH classification is safe. Copyright (C) 2000 S. Karger AG, Basel.

UR - http://www.scopus.com/inward/record.url?scp=0033501097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033501097&partnerID=8YFLogxK

U2 - 10.1159/000006955

DO - 10.1159/000006955

M3 - Review article

VL - 92

SP - 99

EP - 105

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 2

ER -